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Abstract: 
Older populations are more likely to have multiple co-morbid diseases that require multiple 
treatments, which make them a large consumer of medications. As a person grows older, their 
ability to tolerate medications becomes less due to age-related changes in pharmacokinetics and 
pharmacodynamics often heading along a path that leads to frailty. Frail older persons often have 
multiple co-morbidities with signs of impairment in activities of daily living. Prescribing drugs for 
these vulnerable individuals is difficult and is a potentially unsafe activity. Inappropriate prescribing 
in older population can be detected using explicit (criterion-based) or implicit (judgment-based) 
criteria. Unfortunately, most current therapeutic guidelines are applicable only to healthy older 
adults and cannot be generalized to frail patients. These discrepancies should be addressed either by 
developing new criteria or by refining the existing tools for frail older people. The first and foremost 
step is to identify the frail patient in clinical practice by applying clinically validated tools. Once the 
frail patient has been identified, there is a need for specific measures or criteria to assess 
appropriateness of therapy that consider such factors as quality of life, functional status and 
remaining life expectancy and thus modified goals of care. 
 
Introduction: 
The population of older people is growing and is prescribed more medicines.1 This ageing population 
presents a challenge to the healthcare system as older people are more prone to chronic diseases 
and more likely to be prescribed multiple medications.2 Polypharmacy, defined as taking at least five 
drugs, results in increased risk for inappropriate drug use and adverse drug reactions, with attendant 
higher morbidity and hospitalization.2 It is now a major public health concern worldwide. 
 
The appropriate use of available pharmacotherapy in older people requires a balance between the 
risks and benefits of medications. Rational prescribing in older people is complex because of the 
limited evidence on effectiveness of medication in this age group. Factors such as age-related 
changes in drug pharmacokinetics and pharmacodynamics and the presence of multiple co-
morbidities make prescribing a difficult task.3 Moreover, there is limited evidence for drug efficacy 
in older people and this group are more susceptible to adverse drug events (ADEs). Mostly, 
prescribing is guided by evidence from randomized controlled trials, from which older patients, 
particularly those who are frail would be excluded.4 Furthermore, the potential impact of 
medication in frail older people is usually generalized from non-frail or robust populations.5 
Understanding and incorporating the concept of frailty in older people may be of benefit to minimize 
inappropriate medication. This study briefly describes the concept of frailty and some of the tools 
used to measure inappropriate medication use in older people and advocates the incorporation of 
frailty assessment to optimize prescribing practice. 
 
Frailty: definition and measurement 
 Although one person remains hale and hearty, another, who until recently seemed to be well, starts 
to weaken and slow down, sometimes as early as middle age. This is a central issue that is now being 
systematically addressed as why some age well and others do not, often heading along a path that 
ends up in a medical condition known as frailty.5 The term frail is used to identify the vulnerable 
group of older people at high risk of adverse outcomes, including falls, worsening disability, 
prolonged hospital stays, institutionalization and death.6 
 
Frailty can be measured in many ways but there are three established methods. The first method is a 
rules-based approach that identifies frailty as a ‘clinical syndrome or phenotype’ (a set of symptoms 
and signs that tend to occur together, thus characterizing a specific medical condition). The most 
well-known and widely used phenotype, developed by Fried et al. in 20017, identifies frailty on the 
basis of five criteria: weight loss, exhaustion, weak grip strength, slow walking speed and low 
physical activity. People having three or more of these deficits are considered to be frail, those with 
none are considered robust and the term ‘pre-frail’ is used for those with one or two deficits. This 
phenotype has been validated as a predictor of adverse outcomes in large epidemiological studies8 
and was used to identify frailty as the most common condition leading to death in community 
dwelling older people.9 While this model is clinically coherent and reproducible, the omission of 
measures of cognition and mood has made it controversial; some argue that frailty consists of more 
than weakness, slowness and wasting.10 
 
The second method is based on clinicians’ ‘subjective opinion’.11 Although this has strong face 
validity, generalizability is limited. The third method conceptualizes frailty as a ‘multidimensional risk 
state’ that measures frailty based on the quantity rather than by the nature of health problems.12 
The Frailty Index (FI) counts deficits as an aggregation of measures such as symptoms, signs, diseases 
and disabilities with the hypothesis that ‘the more deficits a person has, the more likely that person 
is to be frail’.6 The FI is expressed as a ratio of deficits present to the total number of deficits 
considered. For example, if a patient has 15 of 40 assessed deficits, the FI of that person would be 
15/40 = 0.37. Several studies have shown consistent results generated by the FI which suggests, the 
higher the deficit count, the frailer the person is and more vulnerable to adverse outcomes.13–15 
 
Frailty assessment as a part of a comprehensive geriatric assessment 
 
Comprehensive geriatric assessment (CGA) is a multidimensional process that has long been 
recognized as the best approach to the management of the clinical complexity in older 
populations.16 A CGA explores clinical, functional, cognitive, nutritional and social parameters, 
leading to an all inclusive assessment which helps to optimize long-term treatments, resource 
planning and the use of services.17 The proven benefit of CGA has been supported by several 
studies. One study that randomly assigned 63 frail elderly inpatients with a high probability of 
nursing home placement to an innovative geriatric evaluation unit showed that a multidimensional 
assessment led to an improvement in functional status, discontinuation in the number of prescribed 
drugs, lower mortality and less time spent in hospital.18 Another showed an increased survival in 
frail older patients with a CGA admitted to a geriatric ward as opposed to a general medical ward.19 
CGA has the potential to optimize drug therapy by the detection of both over- and undertreated 
disease conditions.20,21 Importantly, a FI can be derived from the information collected as part of 
CGA.22 
 
These approaches differ not only in their processes for measuring frailty but in their 
conceptualization of the aetiology and implications of frailty itself. The frailty phenotype views frailty 
as a clinical syndrome with the core pathophysiological feature of sarcopenia caused mainly by age-
related changes in hormones.23 In this model, co-morbidity is distinct from frailty, though the 
presence of multiple chronic diseases is recognized, somewhat separately, as necessitating a 
different approach to prescribing.24 The FI approach, on the other hand, conceptualizes frailty as a 
state of increased risk of adverse health outcomes due to a variety of accumulated health deficits.25 
These deficits may or may not relate to sarcopenia, and are sometimes, but not always, secondary to 
co-morbid disease. 
 
Prescribing in frail older people should differ from that in non-frail older people. The primary focus in 
frail patients with life-limiting conditions is to improve quality of life by reducing the severity of 
symptoms or by controlling a disease in the short term.26 Many medications that are commonly 
prescribed in older people such as psychotropic drugs, cardiovascular agents and analgesics are 
commonly associated with high risk of ADEs.27 It is essential that frailty status be considered when 
treatment plans shift away from a curative towards an individualized symptom controlling approach. 
Understanding frailty could assist the treating hospital medical practitioner to better manage 
patients who do not fit well into clinical practice guidelines (CPG) and management algorithms.28 
 
We propose that potentially vulnerable older patients undergo a frailty assessment as a part of a 
comprehensive geriatric assessment as shown in Figure 1. In non-frail older patients, the disease-
specific evidence-based CPG should be followed. In contrast, frail older people would undergo a 
multidimensional approach that evaluates the patient’s life expectancy and identifies the disease 
with the highest priority for treatment instead of treating all diseases according to CPGs. A common 
example in a frail patient with a life expectancy of few months is the use of statins for cardiovascular 
diseases or antiresorptive therapy for osteoporosis which will have no benefit as the onset of 
measurable effects will occur too late to be of benefit.17 If a disease with high priority for treatment 
is identified, the most appropriate therapy based on the recommendations of the CPGs should be 
followed, taking into consideration the frailty status of the patient. This involves the use of various 
tools to optimize appropriate use of medication along with the available Guidance for Prescribing in 
Frail Adults.29 
 
Figure 1. 
 
Criteria for assessing quality of medication prescribing 
 
Inappropriate prescribing in older people can be detected using explicit (criterion-based) or implicit 
(judgment-based) tools. Explicit criteria are derived from expert reports or published reviews. They 
have high reliability and reproducibility but focus mainly on specific drugs and disease states. In 
contrast, implicit criteria are person-specific and explore patient preferences, rather than the 
disease and medications; they rely on evaluator judgment and invariably have low reliability and low 
practical utility.5 The factors addressed by the tools and criteria involved in assessing quality of 
medication prescribing in older people are shown in Table 1. Some criteria assess medications alone, 
some medication and disease states and others factors related to the individual patient. Some 
approaches use a combination of all of these but none of them address frailty although some 
measure the surrogates of frailty. 
Table 1 
The omission of frailty status from established prescribing tools may help to explain the lack of 
clinical benefit secondary to algorithm-based medication reviews. For example, in a randomized 
controlled trial of 872 community dwellers aged over 80 years, home-based medication review by 
pharmacists was associated with a significantly higher rate of hospital admissions and did not 
improve quality of life.30 Similarly, the PLOYMED randomized controlled trial of pharmacist-led 
medication review showed no positive impact on clinical outcomes or quality of life.31 Only a 
medication review underpinned by careful consideration of the health status of the patient 
concerned, including estimation of life expectancy and exploration of individual goals of care, is 
likely to result in clinically meaningful outcomes. 
 
A brief summary of the various approaches follows. 
 
Beers criteria 
 
These criteria present a list of potentially inappropriate medications for older patients, irrespective 
of burden of disease or patient preferences. The Beers criteria are the most widely used since their 
initial development in the USA in 1991. They were designed for older nursing home residents and 
revised in 1997, 2003 and 2012 to enable application in all older patients. They comprise two 
different lists of medications, one considering diagnosis and the other independent of diagnosis. In 
addition, they do not address underprescribing, drug duplication and drug–drug interaction.32 
 
McLeod criteria 
 
These criteria for identifying inappropriate practice in older patients were developed in 1997 in 
Canada and list inappropriate prescribing of non-steroidal anti-inflammatory drugs, cardiovascular 
diseases, psychotropic drugs, analgesics and some miscellaneous drugs. They are based on risk–
benefit ratios and allow the assessment of drug–drug and drug–disease interactions.33 They have 
been criticized as having limited applicability in geriatric clinical practice.39 
Screening Tool of Older Person’s Prescriptions and Screening Tool to Alert doctors to Right 
Treatment 
 These explicit tools were developed to overcome some of the deficiencies of the Beers criteria. They 
capture the common and important instances of potentially inappropriate prescribing in older 
people. The Screening Tool to Alert doctors to Right Treatment (START) criteria report 22 evidence-
based prescribing indicators and highlight the potentially serious errors of prescribing omission in 
older people. The Screening Tool of Older Person’s Prescriptions (STOPP) criteria address 65 
indicators of inappropriate prescribing with special attention to drugs that adversely affect older 
patients at risk of falls, drug–drug interaction, drug–disease interaction and drug duplication.34 
However, both STOPP and START criteria are complex, making their application time consuming. 
 
Inappropriate Medication Use and Prescribing Indicators in Elderly Australians 
 
A list of prescribing indicators for older people based on the most common medications prescribed 
and the most common presenting was developed in Australia. About 48 prescribing indicators were 
identified and a prescribing indicator tool was developed to address the common problem of 
adverse medication-related events. In addition to addressing the medication-related indicators, they 
also address other medication management issues in patients.35 
 
Medication Appropriateness Index 
 
The Medication Appropriateness Index (MAI) is a refined implicit method, developed in USA that 
rates 10 elements of prescribing: indication, effectiveness, dose, correct directions, practical 
directions, drug–drug and drug–disease interactions, duplication, duration and cost.40 Medications 
are rated as appropriate, marginally appropriate, or inappropriate for each criterion. Although the 
MAI has a good reliability in ambulatory settings, there is no clear evidence that it would be effective 
in community settings and the generalizability of the instrument as used by other investigators is 
unknown.36 Furthermore, it does not address the indication of drug. 
 
A 10-step conceptual framework 
 
To minimize inappropriate medications in older population, a quality use of medicine framework 
was developed in Australia. This framework comprises 10 steps that aim to decrease the number of 
medications in older patients to the minimum number of essential drugs. The systematic and 
individualized approach of this framework identifies the medications that are of little or no benefit in 
older patients and ultimately aids in discontinuing them. Unlike most of the alternative methods, it 
focuses on both medication-related and medication management-related aspects of appropriate 
prescribing, which ultimately addresses the gap observed in other tools. However, further studies 
are needed to validate its effectiveness in older patients in various settings.37 
 
The Good Palliative-Geriatric Practice algorithm 
 
This palliative approach was introduced to combat the problem of polypharmacy and improve the 
quality of care in older people in the nursing home setting. The theory behind this algorithm was 
that many drugs can be discontinued in the frailest older people without significant negative 
consequences on mortality, morbidity and the quality of life, with limited financial costs and 
referrals to acute care facilities. Application of this methodology also showed feasibility in 
decreasing medication burden in community-dwelling older patients and in larger randomized 
controlled trials in different clinical settings.38 
 
These criteria are generalized to the older population where the combination of both explicit and 
implicit indicators is suggested as more useful than either one alone.41 However, there are no 
specific criteria to guide prescribing for frail older people or patients with reduced life expectancy.42 
 
Conclusion 
 
Prescribers should be mindful that the criteria used in identifying potentially inappropriate 
prescribing are appropriate for many older people but are not applicable to critically ill or frail 
patients. Improving the existing tools to be more user-friendly or establishing a new specific tool to 
minimize inappropriate prescribing in frail older people is required. The issues can be addressed to 
some extent by incorporating frailty status in the patient assessment and evaluating medications 
based on the guidelines for prescribing in frail adults. By assessing frailty, we are making a more 
informed decision about the physical function and capabilities of a patient and making judgments 
about medication more appropriate to the individual patient. 
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Table 1 
Prescribing indicators that are 
addressed by the tools/criteria 
involved in assessing quality of 
medication prescribing in older 
people 
 
